OPHTHALMOLOGICA update: The peer-reviewed journal of EURETINA edited by Sebastian Wolf
VOL: 237 ISSUE:3
BEST RESULTS FOR MYOPIC CNV ACHIEVED WITH EARLY ANTI-VEGF THERAPY
Early anti-vascular endothelial growth factor (VEGF) treatment of myopic choroidal neovascularisation (CNV) can decrease the recurrence rate and improve visual outcome, according to the findings of a new study. Among 106 eyes with myopic CNV included in a retrospective review, the recurrence rate following initiation of anti-VEGF treatment was only 19% among eyes with a pre-treatment CNV duration of less than two weeks, compared to 25% among those with a pre-treatment CNV duration of two-to-eight weeks, and 52% among those with a pre-treatment duration of eight-to-24 weeks. In addition, CNV duration was a significant predictor of a better final best-corrected visual acuity, even after controlling for other factors (p = 0.042). B.G Moon et al, “Improved Visual Outcome and Low Recurrence with Early Treatment with Intravitreal Anti-Vascular Endothelial Growth Factor in Myopic Choroidal Neovascularization”, Ophthalmologica 2017, Volume 237, Issue 3.
LUTEIN SUPPLEMENTATION IMPROVES VISION AND REDUCES SUBFOVEAL FLUID IN EYES WITH CCSC
Antioxidant supplementation containing lutein can significantly improve vision and reduce subfoveal fluid height in eyes with chronic central serous chorioretinopathy (CCSC), the findings of a randomised study indicate . Among 79 patients randomised who received either the lutein-containing supplement or placebo, those in the supplementation group had significant improvements in their best corrected visual acuity (p = 0.003), but there was no significant change in the placebo group (p = 0.589). In addition, the mean subfoveal fluid height was reduced by 28.6% in the supplementation group (p = 0.028), compared to only to 3.3% in the placebo group (p = 0.898). A Shinojima et al, “A Multicenter Randomized Controlled Study of Antioxidant Supplementation with Lutein for Chronic Central Serous Chorioretinopathy”, Ophthalmologica 2017, Volume 237, Issue 3.
OCT ANGIOGRAPHY SHOWS CHORIOSCAPILLARY CHANGES FOLLOWING PDT FOR CCSC
An optical coherence tomography angiography (OCTA) study of eyes with chronic central serous chorioretinopathy (CCSC) before and after undergoing photodynamic therapy (PDT) appears to confirm the treatment’s theorised mechanism of action. The study involved 33 eyes of 28 patients who underwent OCTA with the split-spectrum amplitude-de-correlation angiography before and after undergoing half-dose PDT. Using the new technology, the study’s authors detected choriocapillary changes that corresponded to an improvement in mean BCVA from 0.29 logMAR to 0.1 logMAR at three months’ follow-up. Y Xu et al, “Effect of Photodynamic Therapy on Optical Coherence Tomography Angiography in Eyes with Chronic Central Serous Chorioretinopathy”, Ophthalmologica 2017, Volume 237, Issue 3.